Abstract:Abstract Introduction/Objective The COVID-19 pandemic exacerbated deficiencies of testing personnel, reagents, supplies and disposables, instruments, and automation in many clinical laboratories. Upon entering respiratory season, a strategy was warranted to optimize laboratory resources when supplies were already limited and expected respiratory season test volume was unknown. An algorithm was devised to prioritize test ordering and TAT based on patient clinical scenario. Methods/Case Report The institutional respiratory season SARS-CoV-2 algorithm was constructed by a multidisciplinary team including infectious disease, infection prevention, laboratory, and IT/LIS leadership. CDC guidance on influenza testing was incorporated. Antigen-based testing was discontinued; only molecular amplification- based platforms with FDA EUA were utilized. Platforms had a range of TAT (20 minutes to 8 hours) and included fully- automated high throughput, rapid random access, point-of-care, and CDC SARS-CoV-2 assays. Test bundles included SARS-CoV-2 (monoplex), or SARS-CoV-2 + fluA&B (triplex), or SARS-CoV-2 + respiratory pathogen panel (multiplex RPP; includes 22 targets, including flu A&B). Results (if a Case Study enter NA) Key factors in the algorithm included whether the patient was outpatient or inpatient, hospital employee or not, symptomatic or not, immunocompetent or immunocompromised, and whether a concurrent order for other respiratory pathogens was included or not. Clinician responses for these factors determined the type of swab collected (wet swab in VTM or dry swab) and how quickly the TAT was indicated for a given patient using a colored-dot sticker system. Priority TAT in decreasing order was symptomatic inpatients, asymptomatic pre- procedure patients, asymptomatic admissions, symptomatic employees, and symptomatic outpatients. Conclusion An algorithm for respiratory pathogen testing during an unprecedented respiratory season prioritizes result TAT to an individual patient’s clinical situation while maximizing laboratory stewardship by eliminating redundant influenza testing and requiring ‘all upfront’ orders to avoid add-on orders that require ‘dumpster diving’ for samples. Limitations include inherent differences in sensitivity, LOD, and specificity when multiple different platforms are utilized to detect the same analytes.

Laboratory testing for respiratory viruses for the clinician

Currently used nucleic acid amplification tests for the detection of viruses and atypicals in acute respiratory infections

At-home testing for respiratory viruses: a minireview of the current landscape

Point-of-care diagnostics for respiratory viral infections

Molecular Diagnosis of Viral Respiratory Infections

Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests

Recent advances in the detection of respiratory virus infection in humans

Clinical Status and Challenges of Respiratory Virus Rapid Detection

Respiratory RNA Viruses

Advanced Point‐of‐Care Testing Technologies for Human Acute Respiratory Virus Detection

The impact of commercial rapid respiratory virus diagnostic tests on patient outcomes and health system utilization

Diagnostic Assays for Respiratory Syncytial Virus Disease

Molecular diagnosis for respiratory viruses：research progresses and clinical applications

Practical updates in clinical antiviral resistance testing

Laboratory testing for common pathogens of respiratory tract infection in pediatrics

An Algorithmic Approach to the Use of Rapid Molecular Diagnostics for SARS-CoV-2, Influenza Viruses, and Other Respiratory Pathogens During an Unprecedented Respiratory Season

Rapid and simple molecular tests for the detection of respiratory syncytial virus: a review

Innovative Technology of Clinical Microbiology for Respiratory Tract Infections:Present and Future

Detection of respiratory viruses directly from clinical samples using next-generation sequencing: A literature review of recent advances and potential for routine clinical use

Real-Time Detection of Influenza A, Influenza B, and Respiratory Syncytial Virus A and B in Respiratory Specimens by Use of Nanoparticle Probes